We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Non-Invasive Sensor for Continuous, Real-Time Blood Data Collection and Analysis to Transform ICU Operations

By HospiMedica International staff writers
Posted on 28 Dec 2023

Currently, frequent invasive blood tests are required to be done to detect changes in the medical condition of hospitalized patients. More...

Now, a non-invasive real-time blood sensor is expected to reduce the need for such frequent invasive blood tests.

The HYLA blood sensor from Inspira Technologies (Ra'anana, Israel) is designed to continuously monitor critical biomarkers like partial oxygen and carbon dioxide pressures, which are vital for identifying health complications and monitoring patient health. This pioneering sensor has demonstrated an impressive 95% accuracy rate when compared to conventional blood gas analyzers. Unlike the periodic blood draws required by standard hospital analyzers, the HYLA sensor offers continuous and real-time monitoring. The non-invasive HYLA blood sensor is attached to the outer walls of a tube that has blood flowing through it and is designed to seamlessly integrate with the company’s INSPIRA ART100 extracorporeal blood circulation device.

Set to revolutionize patient care in Intensive Care Units (ICU), the HYLA Blood Sensor provides uninterrupted, real-time blood data collection and analysis. This technology promises to enhance patient outcomes by offering critical insights and timely alerts, ultimately aiming to refine medical procedures and the efficacy of medical devices. Its potential applications are vast, ranging from ICU monitoring and Invasive Mechanical Ventilation to Extracorporeal Membrane Oxygenation (ECMO), Dialysis, and Cardiopulmonary bypass. This could be a game-changer for patients with conditions like acute respiratory or cardiac failure, pneumonia, acute kidney injury, or those undergoing major heart surgery. The development of the first HYLA variant marks a significant step towards its submission under a 510(k) pathway with the U.S. Food & Drug Administration, which is expected in the second half of 2024.

"With our sensor technology, we are not only enriching our INSPIRA ART device line but also forging a path into the disposables market, setting the stage for groundbreaking developments in healthcare," said Dagi Ben-Noon, CEO of Inspira Technologies.

Related Links:
Inspira Technologies 


Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Ultrasound Needle Guidance System
SonoSite L25
Floor‑Mounted Digital X‑Ray System
MasteRad MX30+
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The AI-based approach identifies lipid regions matched well with histopathology results (Photo courtesy of Hyeong Soo Nam/KAIST)

AI-Based OCT Image Analysis Identifies High-Risk Plaques in Coronary Arteries

Lipid-rich plaques inside coronary arteries are strongly associated with heart attacks and other major cardiac events. While optical coherence tomography (OCT) provides detailed images of vessel structure... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.